Celldex Price To Sales Ratio from 2010 to 2024

CLDX Stock  USD 34.66  0.25  0.72%   
Celldex Therapeutics Price To Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price To Sales Ratio is likely to outpace its year average in 2024. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Celldex Therapeutics' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
279.164222
Current Value
293.12
Quarterly Volatility
249.97150271
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Celldex Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Celldex Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Celldex Therapeutics sales, a figure that is much harder to manipulate than other Celldex Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Celldex Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 374.64 X10 Years Trend
Pretty Stable
   Price To Sales Ratio   
       Timeline  

Celldex Price To Sales Ratio Regression Statistics

Arithmetic Mean241.87
Geometric Mean98.05
Coefficient Of Variation103.35
Mean Deviation197.80
Median277.69
Standard Deviation249.97
Sample Variance62,486
Range883
R-Value0.19
Mean Square Error64,954
R-Squared0.03
Significance0.51
Slope10.42
Total Sum of Squares874,801

Celldex Price To Sales Ratio History

2024 293.12
2023 279.16
2022 886.63
2021 356.16
2020 70.0
2019 9.05
2018 3.28

About Celldex Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Celldex Therapeutics income statement, its balance sheet, and the statement of cash flows. Celldex Therapeutics investors use historical funamental indicators, such as Celldex Therapeutics's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Celldex Therapeutics investors may use each financial statement separately, they are all related. The changes in Celldex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Celldex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Celldex Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 279.16  293.12 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.